Poorman,
I don't agree with the tremendous leap you took. The leap you took is that because not all information is available, that somehow this means that "We just don't know and have very little information to weight the risks and rewards."
Does this thesis take into account that over time, we have seen each of the most ferocious criticisms of this company and its technology evaporate?
Different vaccine? Nope.
Will never end the data collection. Wrong again.
Running out of moolah going broke. Ex-nay.
And on, and on, and on. In fact, the most damning false criticisms are probably left out of this response post because I am a layperson and don't remember the more technical ones.
Let me be careful to say, I am not attributing any of these criticisms to you. But as each of them has come crashing down by virtue of having been proven incorrect, each instance of this brings me confidence. Of note, each of these has come crashing down because material information is made available to investors.
So, knowing the substantial wealth of material information available, I forcefully, but politely, disagree that this stock is pure speculation. I cannot understand how it could be stated that there is very little information to weigh the risks and rewards. Certainly one could say they wish they had more information; that they don't feel there is enough. But I object to the hyperbole that we are simply speculating. This is patently false.
AI
Market Data 
Markets 
